Crescent Biopharma (CBIO) Assets Average (2014 - 2026)

Crescent Biopharma (CBIO) has 13 years of Assets Average data on file, last reported at $219.7 million in Q1 2026.

• Assets Average for Q1 2026 came in at $219.7 million, up 956.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $219.7 million (up 956.07% YoY), and the FY2025 annual result was $138.0 million, up 240.91% from the prior year.
• Assets Average climbed to $219.7 million in Q1 2026 per CBIO's latest filing, from $189.3 million in the prior quarter.
• Over five years, Assets Average peaked at $219.7 million in Q1 2026 and troughed at $20.1 million in Q3 2024.
• A 5-year average of $75.4 million and a median of $60.4 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2024 and 2026: Assets Average plunged 65.12% in 2024, then soared 956.07% in 2026.
• A 5-year view of Assets Average shows it stood at $53.9 million in 2022, then dropped by 8.59% to $49.3 million in 2023, then plunged by 47.91% to $25.7 million in 2024, then soared by 637.72% to $189.3 million in 2025, then rose by 16.08% to $219.7 million in 2026.
• Business Quant data shows CBIO's Assets Average at $219.7 million in Q1 2026, $189.3 million in Q4 2025, and $147.9 million in Q3 2025.